Pulmatrix (NSDQ:PULM) said today that it licensed its inhaled COPD drug to Vectura.
The PUR0200 compound combines tiotropium bromide and Pulmatrix’s iSperse drug-delivery technology. Vectura plans to use its dry powder inhaler device to deliver PUR0200, the company said.
Get the full story at our sister site, Drug Delivery Business News.
